ATS 2024 Final Program

Click on the session title to view the speakers

295

TUESDAY • MAY 21

epidemiology of HIV-related lung disease with a focus on differences between high and low/middle-income countries; 2) pathophysiologic mechanisms of HIV-related lung disease, including the disproportionate impact of smoking on lung health in HIV; 3) RCTs in HIV-related lung disease, including the ongoing DEPTH Trial; 4) clinical considerations in the pulmonary care of people with HIV; and 5) future directions for research and research priorities. 2:15 HIV-Related Lung Disease Epidemiology: A Global Perspective 2:27 Smoking and HIV-Related Lung Disease: Why Is It So Much Worse? 2:39 Pathobiology of HIV and HIV-Associated Influences on Lung Disease 2:51 RCTs in HIV-Related Lung Disease: DEPTH and Other RCTs 3:03 Clinical Considerations When Caring for People with HIV and Lung Disease 3:15 The NHLBI Perspective on the Future of HIV and Lung Disease 3:27 Q&A BEHAVIORAL • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM C90 STATEOF THE SCIENCEON ICU DELIRIUM Assemblies on Critical Care; Behavioral and Health Target Audience ATS attendees from all disciplines who care for patients in the ICU or after discharge from the ICU (i.e., in the hospital or in the outpatient setting) Objectives At the conclusion of this session, the participant will be able to: • describe the current understanding of delirium research related to detection, prevention and treatment to facilitate understanding of the past and present state of delirium research and clinical care Services Research 2:15 p.m. - 3:45 p.m. Marriott Marquis San Diego Marina Grand Ballroom 5-6 (Lobby Level, North Tower)

• explore existing controversies in delirium research and clinical care and describe novel data from studies advancing the of delirium detection, prevention, and treatment • improve attendees’ perspective of delirium and its long-term consequences through the perspective of a survivor of critical illness and emerging long-term data Delirium in ICU patients is strongly associated with adverse outcomes, including increased mortality, longer lengths of stay, poor long-term functional outcomes, and long-term cognitive impairment. Substantial progress has been made in the of delirium in recent years. This session will feature new data on long-term outcomes from a landmark study of delirium in ICU patients, novel methods for delirium detection, a patient perspective, a world leader in aging research, and a discussion of recent delirium trials to provide a high-yield update on the state of the in ICU delirium. 2:15 The 30,000 Foot View: the Past, Present, and Future of Delirium Research 2:30 The Lived Experience of Delirium 2:42 Advancing of the Science of Delirium Detection 2:54 Critical Care Trials in ICU Delirium: New Evidence and the Path Forward 3:06 Rethinking Nonpharmacologic Prevention and Treatment for ICU Delirium 3:18 Long-Term Outcomes After ICU Delirium: 10-Year Follow-Up from the BRAIN-ICU Study 3:30 Panel Discussion C92 SUBSTANCE USE DISORDERS IN PULMONARY, CRITICAL CARE, AND SLEEP MEDICINE Assemblies on Allergy, Immunology and Inflammation; Behavioral and Health Services Research; Critical Care; Environmental, Occupational and Population Health; Nursing; Pediatrics; Pulmonary Infections and Tuberculosis; Pulmonary Rehabilitation; Respiratory Cell and Microbiology 2:15 p.m. - 3:45 p.m. San Diego Convention Center Room 32A-B (Upper Level) BEHAVIORAL • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM

ATS 2024 Conference Program • San Diego, CA